Market closed
Protara Therapeutics/$TARA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protara Therapeutics
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Ticker
$TARA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
31
Website
TARA Metrics
BasicAdvanced
$143M
-
-$2.17
1.68
-
Price and volume
Market cap
$143M
Beta
1.68
52-week high
$4.81
52-week low
$3.19
Financial strength
Current ratio
15.706
Quick ratio
15.536
Long term debt to equity
2.01
Total debt to equity
2.682
Management effectiveness
Return on assets (TTM)
-23.59%
Return on equity (TTM)
-37.88%
Valuation
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-2.239
Growth
Earnings per share change (TTM)
-39.29%
3-year earnings per share growth (CAGR)
-19.85%
TARA News
AllArticlesVideos
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results
Seeking Alpha·1 week ago
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
GlobeNewsWire·2 weeks ago
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Protara Therapeutics stock?
Protara Therapeutics (TARA) has a market cap of $143M as of April 05, 2025.
What is the P/E ratio for Protara Therapeutics stock?
The price to earnings (P/E) ratio for Protara Therapeutics (TARA) stock is 0 as of April 05, 2025.
Does Protara Therapeutics stock pay dividends?
No, Protara Therapeutics (TARA) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Protara Therapeutics dividend payment date?
Protara Therapeutics (TARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Protara Therapeutics?
Protara Therapeutics (TARA) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.